BIORESORBABLE STENT WITH EXTENDED IN VIVO RELEASE OF ANTI-RESTENOTIC AGENT
摘要
<p>A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti- restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of at least 60 days in vivo. The in vivo release profile is determined by in vivo animal experiments involving implanting a series of stents in animals, explanting the stents from the animals at selected time points, and extracting remaining drug from the explanted stents.</p>
申请公布号
WO2008024626(A2)
申请公布日期
2008.02.28
申请号
WO2007US75504
申请日期
2007.08.08
申请人
INNOVATIONAL HOLDINGS LLC;DIAZ, STEPHEN, H.;SHANLEY, JOHN, F.;PARKER, THEODORE, L.;LITVACK, FRANK
发明人
DIAZ, STEPHEN, H.;SHANLEY, JOHN, F.;PARKER, THEODORE, L.;LITVACK, FRANK